Abstract：
OBJECTIVE: To compare the efficacy of the 445-nm blue laser to the 585-nm pulsed dye laser (PDL) and 532-nm potassium-titanyl-phosphate (KTP) laser in the treatment of benign laryngeal lesions.
METHODS: Cochrane Library, PubMed, Scopus, and CINAHL.
METHODS: Following PRISMA guidelines, databases were searched from inception through January 29, 2024, for studies reporting the use of photoangiolytic lasers for treatment of benign laryngeal lesions, including the 585-nm PDL, 532-nm KTP laser, and 445-nm blue laser. Outcome measures included lesion resolution (%), mean differences (Δ) in Voice Handicap Index (VHI-10), and summed dysphonia grade, roughness, and breathiness (GRB) scale.
RESULTS: A total of 45 studies were included for meta-analysis, consisting of 348 patients treated with PDL, 550 patients with KTP laser, and 338 patients with blue laser. Treatment with blue laser resulted in the greatest lesion resolution (94.0%; 95% confidence interval [CI]: 90.2%-96.7%), followed by KTP laser (90.4%; 95% CI: 84.1%-95.2%), and PDL (86.9%; 95% CI: 62.9%-99.2%). VHI-10 improved significantly in patients following treatment with blue laser (Δ13.3; 95% CI: 10.7-16.0; p < 0.0001), KTP laser (Δ10.3; 95% CI: 7.4-13.3; p < 0.0001), and PDL (Δ7.4; 95% CI: 4.8-10.1; p < 0.0001). GRB improved significantly in patients following treatment with blue laser (Δ4.1; 95% CI: 2.9-5.2; p < 0.0001), KTP laser (Δ3.0; 95% CI: 2.0-4.0; p < 0.0001), and PDL (Δ2.5; 95% CI: 0.8-4.2; p = 0.005).
CONCLUSIONS: Photoangiolytic lasers are effective in treating benign laryngeal lesions. Blue lasers are promising for laryngeal laser surgery. Laryngoscope, 2024.
METHODS: Cochrane Library, PubMed, Scopus, and CINAHL.
METHODS: Following PRISMA guidelines, databases were searched from inception through January 29, 2024, for studies reporting the use of photoangiolytic lasers for treatment of benign laryngeal lesions, including the 585-nm PDL, 532-nm KTP laser, and 445-nm blue laser. Outcome measures included lesion resolution (%), mean differences (Δ) in Voice Handicap Index (VHI-10), and summed dysphonia grade, roughness, and breathiness (GRB) scale.
RESULTS: A total of 45 studies were included for meta-analysis, consisting of 348 patients treated with PDL, 550 patients with KTP laser, and 338 patients with blue laser. Treatment with blue laser resulted in the greatest lesion resolution (94.0%; 95% confidence interval [CI]: 90.2%-96.7%), followed by KTP laser (90.4%; 95% CI: 84.1%-95.2%), and PDL (86.9%; 95% CI: 62.9%-99.2%). VHI-10 improved significantly in patients following treatment with blue laser (Δ13.3; 95% CI: 10.7-16.0; p < 0.0001), KTP laser (Δ10.3; 95% CI: 7.4-13.3; p < 0.0001), and PDL (Δ7.4; 95% CI: 4.8-10.1; p < 0.0001). GRB improved significantly in patients following treatment with blue laser (Δ4.1; 95% CI: 2.9-5.2; p < 0.0001), KTP laser (Δ3.0; 95% CI: 2.0-4.0; p < 0.0001), and PDL (Δ2.5; 95% CI: 0.8-4.2; p = 0.005).
CONCLUSIONS: Photoangiolytic lasers are effective in treating benign laryngeal lesions. Blue lasers are promising for laryngeal laser surgery. Laryngoscope, 2024.
摘要：
目的：比较445nm蓝光激光与585nm脉冲染料激光（PDL）和532nm磷酸钛氧钾（KTP）激光治疗喉良性病变的疗效。
方法：Cochrane图书馆，PubMed,Scopus,和CINAHL。
方法：遵循PRISMA指南，从开始到2024年1月29日检索数据库，用于报告使用光血管溶解激光治疗喉良性病变的研究，包括585-nm的PDL,532-nmKTP激光器，和445纳米蓝色激光。结果指标包括病变消退率（%），语音障碍指数(VHI-10)的平均差异(Δ)，总结出发音障碍等级，粗糙度,和呼吸（GRB）量表。
结果：共纳入45项研究进行荟萃分析，由348名接受PDL治疗的患者组成，550例KTP激光患者，338例蓝光激光患者.蓝色激光治疗导致最大的病变分辨率（94.0％;95％置信区间[CI]：90.2％-96.7％），其次是KTP激光（90.4%；95%CI：84.1%-95.2%），和PDL（86.9%；95%CI：62.9%-99.2%）。使用蓝色激光治疗后患者的VHI-10显着改善（Δ13.3;95％CI：10.7-16.0;p<0.0001），KTP激光（Δ10.3；95%CI：7.4-13.3；p<0.0001），和PDL(Δ7.4;95%CI:4.8-10.1;p<0.0001)。使用蓝色激光治疗后患者的GRB显着改善（Δ4.1;95％CI：2.9-5.2;p<0.0001），KTP激光（Δ3.0；95%CI：2.0-4.0；p<0.0001），和PDL(Δ2.5;95%CI:0.8-4.2;p=0.005)。
结论：光血管溶解激光治疗喉良性病变有效。蓝色激光有望用于喉部激光手术。喉镜,2024.
方法：Cochrane图书馆，PubMed,Scopus,和CINAHL。
方法：遵循PRISMA指南，从开始到2024年1月29日检索数据库，用于报告使用光血管溶解激光治疗喉良性病变的研究，包括585-nm的PDL,532-nmKTP激光器，和445纳米蓝色激光。结果指标包括病变消退率（%），语音障碍指数(VHI-10)的平均差异(Δ)，总结出发音障碍等级，粗糙度,和呼吸（GRB）量表。
结果：共纳入45项研究进行荟萃分析，由348名接受PDL治疗的患者组成，550例KTP激光患者，338例蓝光激光患者.蓝色激光治疗导致最大的病变分辨率（94.0％;95％置信区间[CI]：90.2％-96.7％），其次是KTP激光（90.4%；95%CI：84.1%-95.2%），和PDL（86.9%；95%CI：62.9%-99.2%）。使用蓝色激光治疗后患者的VHI-10显着改善（Δ13.3;95％CI：10.7-16.0;p<0.0001），KTP激光（Δ10.3；95%CI：7.4-13.3；p<0.0001），和PDL(Δ7.4;95%CI:4.8-10.1;p<0.0001)。使用蓝色激光治疗后患者的GRB显着改善（Δ4.1;95％CI：2.9-5.2;p<0.0001），KTP激光（Δ3.0；95%CI：2.0-4.0；p<0.0001），和PDL(Δ2.5;95%CI:0.8-4.2;p=0.005)。
结论：光血管溶解激光治疗喉良性病变有效。蓝色激光有望用于喉部激光手术。喉镜,2024.
